By PPN News Staff
The FDA expanded the indication for isavuconazonium sulfate (Cresemba, Astellas Pharma), an azole antifungal, to treat invasive aspergillosis and mucormycosis in pediatric patients as young as 12 months old.
Isavuconazonium for injection is indicated for adults and children 12 months of age and older, and isavuconazonium capsules are indicated for adults and children 6 years and older who weigh 16 kg or more. Isavuconazonium is now the only azole antifungal therapy